Vitaeris

What Vitaeris does

Vitaeris is a Canadian clinical-stage biopharmaceutical company founded in 2016 and headquartered in Vancouver, British Columbia. As a clinical-stage entity, the company is engaged in therapeutic drug development, with operations primarily oriented around advancing pharmaceutical candidates through clinical trials rather than commercial sales. The company operates with a headcount of 11-50 employees, consistent with a small biotech research organization. No specific therapeutic indications, mechanism of action, or technology platform are disclosed in the input data.

Vitaeris secured a single disclosed funding round of $7 million in June 2016, led by HBM Healthcare Investments, indicating an early-stage capital profile typical of venture-backed biotechs in pre-clinical or early clinical development. The company's leadership team includes a Chief Medical Officer (Edward Chong) and a Chief Financial Officer (John Parkinson), reflecting a standard biotech operating structure focused on clinical execution and financial management. The source data indicates Vitaeris was acquired by CSL, a global biotechnology company whose principal businesses are CSL Behring (plasma-derived and recombinant therapies for rare and serious diseases), CSL Seqirus (influenza vaccines), and CSL Vifor (nephrology and iron deficiency).

The input data does not disclose specific therapeutic indications, pipeline assets, mechanism of action, technology platforms, or intellectual property associated with Vitaeris. No revenue, customer, pricing, or partnership information is available. The CSL acquisition suggests Vitaeris' assets were integrated into the broader portfolio, but the specific strategic intent, deal value, timing, and integration trajectory are not documented in the supplied source material. As a result, the company's precise scientific focus, addressable market, and competitive positioning cannot be determined from the inputs provided.

Name

Vitaeris

Website

https://vitaerisbio.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Vitaeris is a Canadian clinical-stage biopharmaceutical company founded in 2016 and headquartered in Vancouver. The firm advances therapeutic candidates through clinical development and was acquired by CSL, integrating its pipeline into the global biotech's rare disease franchise.

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAAAAAI

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors)

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

• Clinical-stage biopharmaceutical
• Antibody therapeutics development
• Immune modulation therapy
• Transplant rejection treatment
• Biotech drug development

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Core offering

Vitaeris is a clinical-stage biopharmaceutical company developing therapeutic candidates. As a privately held Canadian biotech operating in the 11–50 employee range, the company focuses on early-stage drug development activities. The company's specific therapeutic pipeline details are not disclosed in the provided source material.

Product overview

The source data provided does not contain specific information about Vitaeris products or services. The data relates to CSL and its operating subsidiaries (CSL Behring, CSL Seqirus, and CSL Vifor), which are global biotechnology companies. CSL Behring focuses on plasma-derived and recombinant therapies for rare and serious diseases including immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. CSL Seqirus is a major influenza vaccine provider. CSL Vifor focuses on nephrology and iron deficiency. Vitaeris is not mentioned in the provided source data.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical-stage therapeutic development program

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves4 records

Expansion highlights3 records

Emerging players

• AbCellera Biologics: AbCellera is a Canadian antibody discovery and development platform company producing therapeutic mAbs for partners; it is a regional emerging peer comparable in geography and recombinant biologics modality.
• Hansoh Biopharmaceutical: Hansoh is a clinical-to-commercial Chinese biopharmaceutical focused on therapeutic monoclonal antibodies in oncology and immunology, comparable as a recombinant mAb developer with similar stage-gated biologics pipeline approach.
• BridgeBio Pharma: BridgeBio is a clinical-to-commercial biotech developing biologic and small-molecule therapies for genetic and rare diseases, comparable as an emerging biologics developer with orphan-like indication strategies similar in shape to Vitaeris.

Broad incumbents

• CSL Behring: CSL Behring — Vitaeris' parent — is the broadest plasma-derived and recombinant therapy provider for rare and serious diseases (immunology, hematology, transplant), serving as the incumbent commercialization engine and a directly relevant incumbent in Vitaeris' therapeutic categories.
• Vertex Pharmaceuticals: Vertex is a global biotech with a growing rare-disease and biologics footprint (Casgevy gene therapy in partnership with CRISPR Tx) that increasingly overlaps Vitaeris' position as an advanced-therapy biologic developer within CSL's broader rare-disease orbit.
• Astellas Pharma: Astellas is a global pharma anchored by its transplant franchise (Prograf/tacrolimus, Xtandi), making it the dominant incumbent player in transplantation immunosuppression — the same therapeutic arena Vitaeris targets.
• Takeda Pharmaceutical: Takeda operates a sizable immunology and biologics franchise (including post-Shire rare disease assets) overlapping with Vitaeris' therapeutic biologics and rare-disease positioning.
• Bristol Myers Squibb: BMS operates a major immunology and biologics franchise (Orencia/belatacept for transplant, Zeposia, etc.), overlapping directly with Vitaeris' transplant-immunology biologic positioning as a broad incumbent in the same therapeutic space.

Direct peers

• Eledon Pharmaceuticals: Eledon is a clinical-stage biotech developing novel immunosuppression therapies (anti-CD40L antibody tegoprubart) for organ transplantation, directly comparable to Vitaeris' clinical-stage biologic strategy targeting transplant immunology.
• Veloxis Pharmaceuticals: Veloxis is a transplant-focused specialty pharma (now an Asahi Kasei company) marketing Envarsus XR (tacrolimus) for organ transplant patients, making it a direct transplant-immunosuppression peer comparable in target indication to Vitaeris.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat1 record

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/vitaerisbio
• LinkedInlinkedin.com/company/vitaeris-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vitaeris